ADMA Biologics (NASDAQ: ADMA) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares ADMA Biologics and Cidara Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ADMA Biologics $12.29 million 5.86 -$17.61 million ($1.75) -1.59
Cidara Therapeutics N/A N/A -$55.96 million ($3.55) -2.46

ADMA Biologics has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ADMA Biologics and Cidara Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -198.99% -791.24% -63.60%
Cidara Therapeutics N/A -75.72% -62.42%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ADMA Biologics and Cidara Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 1 0 3.00
Cidara Therapeutics 0 1 8 1 3.00

ADMA Biologics presently has a consensus price target of $13.00, suggesting a potential upside of 365.95%. Cidara Therapeutics has a consensus price target of $13.65, suggesting a potential upside of 56.00%. Given ADMA Biologics’ higher possible upside, equities analysts clearly believe ADMA Biologics is more favorable than Cidara Therapeutics.

Institutional and Insider Ownership

34.6% of ADMA Biologics shares are held by institutional investors. Comparatively, 66.1% of Cidara Therapeutics shares are held by institutional investors. 60.4% of ADMA Biologics shares are held by company insiders. Comparatively, 18.9% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

ADMA Biologics has a beta of 2.48, suggesting that its share price is 148% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

ADMA Biologics Company Profile

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.